Price
264.85
-1.36%52W Range
Market Cap
₹925.37 Cr
Traded: ₹2.72 Cr (0.29%) 0.0x
Free Float: ₹436.03 Cr (0.62% of FF traded)
Volume · 60D trend
1.02 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +9.0% | +10.0% | +5.0% | -- | +12.0% | Stable |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | +19.0% | +21.0% | +68.0% | -11.0% | -- | Stable |
| Profit | +26.0% | +31.0% | +80.0% | -- | +60.0% | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022PDF ↗ | Sep 2022PDF ↗ | Jun 2022PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 163 | 172 | 133 | 161 | 131 | 139 | 146 | 144 | 146 | 133 | 126 | 124 | 117 |
| Expenses | 139 | 142 | 120 | 141 | 120 | 121 | 124 | 127 | 133 | 119 | 119 | 118 | 120 |
| Operating Profit | 24 | 30 | 14 | 20 | 11 | 18 | 21 | 17 | 13 | 14 | 6 | 6 | -3 |
| OPM % | 15.0% | 17.0% | 10.0% | 12.0% | 8.0% | 13.0% | 15.0% | 12.0% | 9.0% | 11.0% | 5.0% | 5.0% | -3.0% |
| Other Income | 0 | 2 | 1 | 2 | 1 | 26 | 1 | 1 | 1 | -3 | 0 | 1 | 2 |
| Interest | 8 | 9 | 10 | 10 | 8 | 7 | 8 | 8 | 6 | 8 | 7 | 4 | 3 |
| Depreciation | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 14 | 19 | 1 | 8 | 1 | 34 | 10 | 7 | 5 | 1 | -3 | -1 | -7 |
| Tax % | 1.0% | -6.0% | 5.0% | 2.0% | 0.0% | 1.0% | 0.0% | -2.0% | 6.0% | -11.0% | 8.0% | 25.0% | -3.0% |
| Net Profit | 13 | 20 | 1 | 8 | 1 | 34 | 10 | 7 | 5 | 1 | -3 | -1 | -7 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | -1 | 0 | 0 | 0 |
| EPS (Rs) | 4.1 | 6.2 | 0.4 | 2.5 | 0.3 | 10.3 | 3.1 | 2.3 | 1.4 | 0.3 | -1.0 | -0.3 | -2.2 |
| Sales Growth (YoY) | 24.4% | 23.7% | -8.9% | 11.8% | -10.3% | 4.5% | 15.9% | 16.1% | 24.8% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -5.2% | 29.3% | -17.4% | 22.9% | -5.8% | -4.8% | 1.4% | -1.4% | 9.8% | 5.6% | 1.6% | 6.0% | -- |
| OP Growth (YoY) | 118.2% | 66.7% | -33.3% | 17.6% | -15.4% | 28.6% | 250.0% | 183.3% | 533.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | -20.0% | 114.3% | -30.0% | 81.8% | -38.9% | -14.3% | 23.5% | 30.8% | -7.1% | 133.3% | 0.0% | 300.0% | -- |
| Profit Growth (YoY) | 1197.0% | 145.0% | -88.0% | 9.0% | -78.0% | 414.0% | 413.0% | 927.0% | 165.0% | -74.0% | -986.0% | -53.0% | -742.0% |
| EPS Growth (YoY) | 1181.3% | -39.8% | -88.2% | 8.9% | -77.6% | 3212.9% | 414.0% | 933.3% | 164.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -33.7% | 1570.3% | -84.9% | 665.6% | -96.9% | 227.1% | 39.6% | 57.3% | 361.3% | 131.0% | -270.4% | 87.8% | -- |
| OP Margin | 14.7% | 17.4% | 10.5% | 12.4% | 8.4% | 12.9% | 14.4% | 11.8% | 8.9% | 10.5% | 4.8% | 4.8% | -2.6% |
| Net Margin | 8.0% | 11.6% | 0.8% | 5.0% | 0.8% | 24.5% | 6.8% | 4.9% | 3.4% | 0.8% | -2.4% | -0.8% | -6.0% |
| Material Cost % | 46.2% | 49.0% | 46.4% | 50.9% | 50.5% | 50.5% | 48.7% | 52.9% | 58.1% | 55.9% | 60.7% | 61.4% | 64.8% |
| Employee Cost % | 17.6% | 15.4% | 19.7% | 16.4% | 19.2% | 14.4% | 16.9% | 14.6% | 14.4% | 15.6% | 15.2% | 15.8% | 18.4% |
| P/S | 1.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 20.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 15.68 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.
Press Release on Un-audited Financial Results for the quarter ended 30th June, 2026
Outcome of the Board Meeting held on August 11, 2026
Outcome of the Board Meeting held on August 11, 2026
Outcome of the Board Meeting held on August 11, 2026
Financial Results for the first quarter ended 30th June, 2026
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company''s Facilty.
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent ....
The Exchange has sought clarification from Wanbury Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured, guaranteed, senior, taxable, non-cumulative, unrated, ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Investor Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March, 2026 and is also available on the website of the Company at www.wanbury.com
Outcome of the Board Meeting - Change in Management
Outcome of the Board Meeting dated 26.06.2026
Closure of Trading Window
Press Release dated 25.06.2026 titled Intimation of pledge being released on equity shares held by the Promoter Group and reduction in rate of interest from 12.5% per annum to Sub 10% per annum.
Press Release on Quality inspection by the Therapeutic Goods Administration (TGA) at Tanuku, Andhra Pradesh
Press Release on Launch of New APIs.
Press Release on Q4 & Year ended FY 2026 for Audited Financial Results
Pursuant to Regulation 30 (6) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, we wish to inform you that the Company is organizing a plant visit and management meeting ....
Outcome of the Board Meeting held on 29.05.2026
Outcome of the Board Meeting held on 29.05.2026
The Board Meeting to be held on 14/05/2026 has been revised to 29/05/2026 The Board Meeting to be held on 14/05/2026 has been revised to 29/05/2026
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....
Press Release on MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection.
Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2026.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Trading Window Closure for the last quarter and year ended 31st March, 2026.
Press release dated 24th March, 2026.
Press release dated 12.03.2026
Investor Presentation on Un-audited Financial Results (UFR) for the quarter and nine months ended 31st December, 2025.
Press Release on Un-audited Financial Results (UFR) for the quarter and nine months ended 31st December, 2025.
Grant of 60000 stock options (ESOP''s) to the employees of the Company.
Outcome of the Board meeting held on 05.02.2026 - Allotment of 47,400 Equity Shares of the Company to eligible employee of the Company who has exercised their vested options under Wanbury ....
Un-audited financial results of the Company for the third quarter and nine months ended 31st December, 2025 alongwith Limited Review Report.
Outcome of Board Meeting held on February 05, 2026
Press Release with titled "Wanbury Achieves First Sales Invoicing and commercial shipment milestone on 30th January, 2026 for the new Product, High-Demand Anaesthetic API-Production Ramp-Up ....
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve Intimation of Board Meeting under Regulation ....
Wanbury Launches Commercial production of key anaesthetic API at Tanuku Facility.
Certificate under reg. 74 (5) of SEBI (DP) Reg, 2018
Intimation under Regulation 30 and Schedule III (LODR) Regulations, 2015 on Re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as the Non-Executive Independent Director ....
Summary of proceedings of Extra Ordinary General Meeting (EOGM) dated 05.01.2026.
Closure of Trading Window
Notice of Book Closure for the purpose of Extra-Ordinary General Meeting (EOGM) to be held on 5th January, 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
Newspaper Clipping-Information regarding Extra Ordinary General Meeting to be held through VC/OAVM.
Notice of the Extra Ordinary General Meeting of Wanbury Limited to be held on 5th January, 2026 through Video Conferencing (VC) / Other Audio Visual Means (OVAM).
Annual Reports
15Credit Ratings
4Held by ETFs
1 ETFs hold wanbury · sorted by weight
Held by Mutual Funds
1 schemes hold wanbury · sorted by weight